Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

VP4896

Small molecule · developed by Voyager Pharmaceutical

Phase 3 Most advanced trial (none active)
VYGR Developer
1 Registered trials

What is VP4896?

VP4896 is an investigational small-molecule drug studied in Alzheimer's Disease.

At a glance

Drug type
Small molecule
Therapy area
Neurology
Developer
Voyager Pharmaceutical Corporation (VYGR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00231946 Phase 3 Alzheimer's Disease Completed VYGR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer's Disease

More from Voyager Pharmaceutical

Follow VYGR, the company behind VP4896

See VYGR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VYGR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.